Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 91
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Immunity ; 50(1): 212-224.e4, 2019 01 15.
Artículo en Inglés | MEDLINE | ID: mdl-30650377

RESUMEN

Microbiota are thought to influence the development and progression of inflammatory bowel disease (IBD), but determining generalizable effects of microbiota on IBD etiology requires larger-scale functional analyses. We colonized germ-free mice with intestinal microbiotas from 30 healthy and IBD donors and determined the homeostatic intestinal T cell response to each microbiota. Compared to microbiotas from healthy donors, transfer of IBD microbiotas into germ-free mice increased numbers of intestinal Th17 cells and Th2 cells and decreased numbers of RORγt+ Treg cells. Colonization with IBD microbiotas exacerbated disease in a model where colitis is induced upon transfer of naive T cells into Rag1-/- mice. The proportions of Th17 and RORγt+ Treg cells induced by each microbiota were predictive of human disease status and accounted for disease severity in the Rag1-/- colitis model. Thus, an impact on intestinal Th17 and RORγt+ Treg cell compartments emerges as a unifying feature of IBD microbiotas, suggesting a general mechanism for microbial contribution to IBD pathogenesis.


Asunto(s)
Colitis/microbiología , Microbioma Gastrointestinal/genética , Enfermedades Inflamatorias del Intestino/inmunología , Enfermedades Inflamatorias del Intestino/microbiología , ARN Ribosómico 16S/genética , Linfocitos T Reguladores/inmunología , Células Th17/metabolismo , Animales , Diferenciación Celular , Colitis/inducido químicamente , Colitis/inmunología , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Homeostasis , Humanos , Ratones , Ratones Endogámicos C57BL , Miembro 3 del Grupo F de la Subfamilia 1 de Receptores Nucleares/metabolismo
2.
Mol Biol Evol ; 39(9)2022 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-35975687

RESUMEN

Host-dependency factors have increasingly been targeted to minimize antiviral drug resistance. In this study, we have demonstrated that inhibition of p38 mitogen-activated protein kinase (a cellular protein) suppresses buffalopox virus (BPXV) protein synthesis by targeting p38-MNK1-eIF4E signaling pathway. In order to provide insights into the evolution of drug resistance, we selected resistant mutants by long-term sequential passages (P; n = 60) in the presence of p38 inhibitor (SB239063). The P60-SB239063 virus exhibited significant resistance to SB239063 as compared to the P60-Control virus. To provide mechanistic insights on the acquisition of resistance by BPXV-P60-SB239063, we generated p38-α and p38-ϒ (isoforms of p38) knockout Vero cells by CRISPR/Cas9-mediated genome editing. It was demonstrated that unlike the wild type (WT) virus which is dependent on p38-α isoform, the resistant virus (BPXV-P60-SB239063) switches over to use p38-ϒ so as to efficiently replicate in the target cells. This is a rare evidence wherein a virus was shown to bypass the dependency on a critical cellular factor under selective pressure of a drug.


Asunto(s)
Antivirales , Virus Vaccinia , Animales , Antivirales/farmacología , Chlorocebus aethiops , Farmacorresistencia Viral/genética , Virus Vaccinia/metabolismo , Células Vero , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
3.
BMC Nephrol ; 24(1): 245, 2023 08 22.
Artículo en Inglés | MEDLINE | ID: mdl-37608357

RESUMEN

BACKGROUND: On December 29, 2021, during the delta wave of the Coronavirus Disease 2019 (COVID-19) pandemic, the stock of premanufactured solutions used for continuous kidney replacement therapy (CKRT) at the University of New Mexico Hospital (UNMH) was nearly exhausted with no resupply anticipated due to supply chain disruptions. Within hours, a backup plan, devised and tested 18 months prior, to locally produce CKRT dialysate was implemented. This report describes the emergency implementation and outcomes of this on-site CKRT dialysate production system. METHODS: This is a single-center retrospective case series and narrative report describing and reporting the outcomes of the implementation of an on-site CKRT dialysate production system. All adults treated with locally produced CKRT dialysate in December 2021 and January 2022 at UNMH were included. CKRT dialysate was produced locally using intermittent hemodialysis machines, hemodialysis concentrate, sterile parenteral nutrition bags, and connectors made of 3-D printed biocompatible rigid material. Outcomes analyzed included dialysate testing for composition and microbiologic contamination, CKRT prescription components, patient mortality, sequential organ failure assessment (SOFA) scores, and catheter-associated bloodstream infections (CLABSIs). RESULTS: Over 13 days, 22 patients were treated with 3,645 L of locally produced dialysate with a mean dose of 20.0 mL/kg/h. Fluid sample testing at 48 h revealed appropriate electrolyte composition and endotoxin levels and bacterial colony counts at or below the lower limit of detection. No CLABSIs occurred within 7 days of exposure to locally produced dialysate. In-hospital mortality was 81.8% and 28-day mortality was 68.2%, though illness severity was high, with a mean SOFA score of 14.5. CONCLUSIONS: Though producing CKRT fluid with IHD machines is not novel, this report represents the first description of the rapid and successful implementation of a backup plan for local CKRT dialysate production at a large academic medical center in the U.S. during the COVID-19 pandemic. Though conclusions are limited by the retrospective design and limited sample size of our analysis, our experience could serve as a guide for other centers navigating similar severe supply constraints in the future.


Asunto(s)
COVID-19 , Infecciones Relacionadas con Catéteres , Terapia de Reemplazo Renal Continuo , Adulto , Humanos , Soluciones para Diálisis , Pandemias , Estudios Retrospectivos
4.
Int J Phytoremediation ; 25(11): 1501-1509, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36694290

RESUMEN

The PAH degrading microbial consortium was collected from sodic soil of the nursery of Guru Jambheshwar University of Science and Technology, Hisar, Haryana (India). And the soil was artificially amended with phenanthrene and naphthalene to isolate the PAHs degrading microbial consortium. The diversity of microbial consortium was analyzed using the NGS (Next Generation Sequencing) based metagenomic approach. The result of diversity analysis showed species Tepidanaerobacter syntrophicus, Sphingomonas oliophenolica, Arthrobacter psychrochitinipnius, Bifidobacterium bombi, Nocardiodies islandensis, Rhodovibrio sodomensis, Thiorhodococus pfennigii, Aeromicrobium ponti, Steroidobacter dentrificans, Actinomaduria maheshkhaliensis, Dactylosporangium maewongense, Pelotomaculum isophthalicicum, and Nocardioides islandensis were present in the consortium. Moreover, Sphingomonas, Arthrobacter, Sphingobium, Azospirillium, Thirohodococcus, and Pelotomaculum were the prominent pollutant degrader genera in the microbial consortium. Since the bioremediation of these pollutants occurs with a significant reduction in toxicity, the study's perspective is to use this type of consortium for bioremediation of specifically contaminated soil.


The present work's novelty was to find the helpful microbial consortium for the bioremediation of toxic compounds such as naphthalene and phenanthrene. In this study, the degradation of such compounds was done by the various communities of genera like Bifidobacterium, Conexibacter, Sterodobacter, Rhodovibrio, Arthrobacter, Actinomadura, and Euzebya, which are rarely described in the earlier researches. Therefore, this study will enhance the quality of future research.


Asunto(s)
Microbiota , Hidrocarburos Policíclicos Aromáticos , Contaminantes del Suelo , Biodegradación Ambiental , Suelo , Consorcios Microbianos , Microbiología del Suelo
5.
Rev Med Virol ; 31(5): 1-16, 2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-33450133

RESUMEN

Mitogen-activated protein kinases (MAPKs) play a key role in complex cellular processes such as proliferation, development, differentiation, transformation and apoptosis. Mammals express at least four distinctly regulated groups of MAPKs which include extracellular signal-related kinases (ERK)-1/2, p38 proteins, Jun amino-terminal kinases (JNK1/2/3) and ERK5. p38 MAPK is activated by a wide range of cellular stresses and modulates activity of several downstream kinases and transcription factors which are involved in regulating cytoskeleton remodeling, cell cycle modulation, inflammation, antiviral response and apoptosis. In viral infections, activation of cell signalling pathways is part of the cellular defense mechanism with the basic aim of inducing an antiviral state. However, viruses can exploit enhanced cell signalling activities to support various stages of their replication cycles. Kinase activity can be inhibited by small molecule chemical inhibitors, so one strategy to develop antiviral drugs is to target these cellular signalling pathways. In this review, we provide an overview on the current understanding of various cellular and viral events regulated by the p38 signalling pathway, with a special emphasis on targeting these events for antiviral drug development which might identify candidates with broad spectrum activity.


Asunto(s)
Antivirales/farmacología , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Replicación Viral/efectos de los fármacos , Proteínas Quinasas p38 Activadas por Mitógenos , Humanos , Quinasas de Proteína Quinasa Activadas por Mitógenos/metabolismo
6.
Phytother Res ; 35(5): 2745-2757, 2021 May.
Artículo en Inglés | MEDLINE | ID: mdl-33511704

RESUMEN

A severe acute respiratory syndrome is an unusual type of contagious pneumonia that is caused by SARS coronavirus. At present, the whole world is trying to combat this coronavirus disease and scientific communities are putting rigorous efforts to develop vaccines. However, there are only a few specific medical treatments for SARS-CoV-2. Apart from other public health measures taken to prevent this virus, we can boost our immunity with natural products. In this article, we have highlighted the potential of common spices and herbs as antiviral agents and immunity boosters. A questionnaire-based online survey has been conducted on home remedies during COVID-19 among a wide range of peoples (n-531) of different age groups (13-68 years) from various countries. According to the survey, 71.8% of people are taking kadha for combating infection and boosting immunity. Most people (86.1%) think that there is no side effect of kadha while 13.9% think vice versa. A total of 93.6% of people think that spices are helpful in curing coronavirus or other viral infection as well as boosting immunity. Most people are using tulsi drops, vitamin C, and chyawanprash for boosting their immunity. Therefore, we conclude from the survey and available literature that spices and herbs play a significant role against viral infections.


Asunto(s)
Tratamiento Farmacológico de COVID-19 , Adolescente , Adulto , Anciano , Antivirales/uso terapéutico , Humanos , Persona de Mediana Edad , SARS-CoV-2 , Especias , Adulto Joven
7.
Clin Gastroenterol Hepatol ; 18(3): 612-619.e1, 2020 03.
Artículo en Inglés | MEDLINE | ID: mdl-31009795

RESUMEN

BACKGROUND & AIMS: Fecal microbiota transplantation (FMT) is commonly used to treat Clostridium difficile infection (CDI). CDI is an increasing cause of diarrheal illness in pediatric patients, but the effects of FMT have not been well studied in children. We performed a multi-center retrospective cohort study of pediatric and young adult patients to evaluate the efficacy, safety, and factors associated with a successful FMT for the treatment of CDI. METHODS: We performed a retrospective study of 372 patients, 11 months to 23 years old, who underwent FMT at 18 pediatric centers, from February 1, 2004, to February 28, 2017; 2-month outcome data were available from 335 patients. Successful FMT was defined as no recurrence of CDI in the 2 months following FMT. We performed stepwise logistic regression to identify factors associated with successful FMT. RESULTS: Of 335 patients who underwent FMT and were followed for 2 months or more, 271 (81%) had a successful outcome following a single FMT and 86.6% had a successful outcome following a first or repeated FMT. Patients who received FMT with fresh donor stool (odds ratio [OR], 2.66; 95% CI, 1.39-5.08), underwent FMT via colonoscopy (OR, 2.41; 95% CI, 1.26-4.61), did not have a feeding tube (OR, 2.08; 95% CI, 1.05-4.11), or had 1 less episode of CDI before FMT (OR, 1.20; 95% CI, 1.04-1.39) had increased odds for successful FMT. Seventeen patients (4.7%) had a severe adverse event during the 3-month follow-up period, including 10 hospitalizations. CONCLUSIONS: Based on the findings from a large multi-center retrospective cohort, FMT is effective and safe for the treatment of CDI in children and young adults. Further studies are required to optimize the timing and method of FMT for pediatric patients-factors associated with success differ from those of adult patients.


Asunto(s)
Clostridioides difficile , Infecciones por Clostridium , Niño , Infecciones por Clostridium/terapia , Trasplante de Microbiota Fecal , Heces , Humanos , Recurrencia , Estudios Retrospectivos , Resultado del Tratamiento , Adulto Joven
8.
Microb Pathog ; 142: 103994, 2020 Jan 24.
Artículo en Inglés | MEDLINE | ID: mdl-31988007

RESUMEN

Cytokines might be involved in spontaneous abortion by triggering inflammatory mediators (Cyclooxygenases (Cox)) leading to spontaneous abortion in Chlamydia trachomatis (Ct)-infected women. Study aimed to quantitate the expression of pro-inflammatory cytokines (TNF-α, IFN-γ, IL-8) and Cox-2 in endometrial curettage tissue (ECT) of Spontaneous Aborters (SA). SA (n = 135) and 120 age-matched controls were enrolled from SJH, New Delhi, India. PCR was performed for detection of Ct MOMP gene (537 bp) in ECT. mRNA expression of pro-inflammatory cytokines and Cox-2 was assessed by real-time qPCR. Data was statistically evaluated. 14.8% SA were diagnosed as Ct-positive. Elevated expression of TNF-α, IFN-γ, IL-8 and Cox-2 was observed in Ct-infected SA. Ct-positive recurrent aborters showed significantly higher cytokine expression. Significant positive correlation was found between expression of Cox-2 and TNF-α in infected SA. Data suggested an increased expression of Th-1 cytokines, particularly TNF-α that induced Cox-2 expression in ECT, leading to spontaneous abortion in Ct-infected pregnant women.

9.
J Pediatr Gastroenterol Nutr ; 70(3): 389-403, 2020 03.
Artículo en Inglés | MEDLINE | ID: mdl-32079889

RESUMEN

The rate of pediatric inflammatory bowel disease (IBD) has been increasing over the last decade and this increase has occurred most rapidly in the youngest children diagnosed <6 years, known as very early-onset inflammatory bowel disease (VEO-IBD). These children can present with more extensive and severe disease than older children and adults. The contribution of host genetics in this population is underscored by the young age of onset and the distinct, aggressive phenotype. In fact, monogenic defects, often involving primary immunodeficiency genes, have been identified in children with VEO-IBD and have led to targeted and life-saving therapy. This position paper will discuss the phenotype of VEO-IBD and outline the approach and evaluation for these children and what factors should trigger concern for an underlying immunodeficiency. We will then review the immunological assays and genetic studies that can facilitate the identification of the underlying diagnosis in patients with VEO-IBD and how this evaluation may lead to directed therapies. The position paper will also aid the pediatric gastroenterologist in recognizing when a patient should be referred to a center specializing in the care of these patients. These guidelines are intended for pediatricians, allied health professionals caring for children, pediatric gastroenterologists, pediatric pathologists, and immunologists.


Asunto(s)
Colitis , Gastroenterología , Enfermedades Inflamatorias del Intestino , Adolescente , Adulto , Niño , Humanos , Enfermedades Inflamatorias del Intestino/diagnóstico , Enfermedades Inflamatorias del Intestino/genética , Enfermedades Inflamatorias del Intestino/terapia , Estado Nutricional , Fenotipo , Estados Unidos
10.
Arch Microbiol ; 201(9): 1195-1205, 2019 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-31172252

RESUMEN

Awareness of the consumer has increased the demand of safe and chemical-free foods, and consequently it has increased the demand of antibacterial bioactive compounds. In the present study, antibacterial compound produced by a local bacterial isolate NSD MTCC 10072, showing antagonistic activity against six human pathogens, was isolated, partially purified and characterized. Maximum production of antibacterial compound was observed between 51 and 60 h after seeding. The antibacterial activity of the compound was found to be thermostable up to 80 °C for 60 min and its efficacy was very good between pH 4 and 12. Minimum inhibitory concentration (25.84 µg/µl) of the antibacterial compound was observed against Streptococcus aureus NICM 2901. GC-MS analysis of the bacterium secreted chemical compound (C11H18N2O2) was used to identify the antimicrobial compound as Pyrrolo(1,2-a) pyrazine-1,4-dione, hexahydro-3-(2-methylpropyl). In Silico studies showed that the antimicrobial compound is non-toxic, non-irritating and followed Lipinski-type properties which suggested that the compound could be used as potential drug against different human pathogens.


Asunto(s)
Antibacterianos/farmacología , Bacillus cereus/metabolismo , Proteínas Bacterianas/farmacología , Agentes de Control Biológico/farmacología , Antibacterianos/metabolismo , Bacillus cereus/aislamiento & purificación , Bacillus subtilis/efectos de los fármacos , Proteínas Bacterianas/metabolismo , Agentes de Control Biológico/metabolismo , Escherichia coli/efectos de los fármacos , Humanos , Pruebas de Sensibilidad Microbiana , Mycobacterium/efectos de los fármacos , Pirroles/química , Pirroles/farmacología , Staphylococcus aureus/efectos de los fármacos
11.
J Paediatr Child Health ; 59(3): 597-598, 2023 03.
Artículo en Inglés | MEDLINE | ID: mdl-36718856
13.
Indian J Microbiol ; 63(3): 231-234, 2023 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-37781007
14.
Microb Pathog ; 110: 152-158, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28648621

RESUMEN

The study aimed to elucidate role of Th1/Th2/Th17 cytokines in the immunopathogenesis of spontaneous abortion in Chlamydia trachomatis (Ct)-positive first-trimester aborters. Endometrial curettage tissue and serum were collected from 145 aborters (spontaneous abortion (SA) group, n = 85; recurrent miscarriage (RM) group, n = 60) and 120 controls attending Department of Obstetrics & Gynecology at Safdarjung hospital, New Delhi (India). Polymerase chain reaction was used to detect Ct plasmid/MOMP, while commercial cytometric bead array kit was utilized to estimate circulating serum cytokines. 13.7% aborters were Ct-positive, however, none was found to be infected among controls. IFN-γ, TNF-α, IL-2, IL-6 and IL-17A cytokines were significantly increased in SA group/RM group (Ct-infected) versus controls. IL-4 showed no difference between groups, while IL-10 was significantly elevated in controls versus Ct-infected subjects in SA group/RM group. Furthermore, IFN-γ, TNF-α, IL-6, IL-17A cytokines were significantly elevated in Ct-positive RM group versus Chlamydia-infected SA group. However, IL-2, IL-4 and IL-10 cytokines showed no significant difference between Ct-positive SA group versus infected RM group. Positive correlation was found between few cytokines (TNF-α and IFN-γ/IL-17A; IL-17A and IFN-γ/IL-6) in Ct-positive aborters. Our study clearly established the role of Th1/Th2/Th17 cytokines in the pathogenesis of spontaneous abortion in Ct-infected subjects and found that Chlamydia-positive recurrent aborters had a predominant Th1/Th17 bias.


Asunto(s)
Aborto Espontáneo/inmunología , Infecciones por Chlamydia/inmunología , Chlamydia trachomatis/inmunología , Chlamydia trachomatis/patogenicidad , Citocinas/sangre , Linfocitos T Colaboradores-Inductores/metabolismo , Aborto Habitual , Aborto Espontáneo/etiología , Aborto Espontáneo/microbiología , Adolescente , Adulto , Infecciones por Chlamydia/complicaciones , Chlamydia trachomatis/genética , Chlamydia trachomatis/aislamiento & purificación , Femenino , Humanos , India , Interferón gamma/sangre , Interleucina-10/sangre , Interleucina-17/sangre , Interleucina-2/sangre , Interleucina-6/sangre , Embarazo , Factor de Necrosis Tumoral alfa/sangre , Adulto Joven
16.
J Pediatr Gastroenterol Nutr ; 62(6): 863-6, 2016 06.
Artículo en Inglés | MEDLINE | ID: mdl-27213249

RESUMEN

OBJECTIVES: Natalizumab is a humanized monoclonal antibody inhibiting lymphocyte migration and prescribed in patients with Crohn disease (CD) failing anti-tumor necrosis factor (TNF) therapies. Because of the risk of progressive multifocal leukoencephalopathy in patients with John Cunningham virus (JCV) positive, natalizumab is not widely used in clinical practice. Published experience of the use of natalizumab in pediatric patients is lacking. We aimed to describe the experience of natalizumab in patients with CD, including those who are JCV positive, at a tertiary care pediatric inflammatory bowel disease center. METHODS: A retrospective chart review was performed in patients with CD <21 years receiving natalizumab therapy before March 2014. Patient and disease information, prior treatments and response to natalizumab, including Harvey Bradshaw Index (HBI), were recorded. Descriptive statistics were computed. RESULTS: Nine patients received natalizumab with a median age at diagnosis of 10 (range 7-16) years and median disease duration 72 (range 13-156) months. All of the patients had failed at least 1 anti-TNF agent. At baseline, the median HBI was 8 (IQR 6.5-11). By week 10, the median HBI was 4.5 (IQR 2-6), with 4 of 8 (50%) patients with CD being in remission. Forty-four percent (4/9) of patients were JCV antibody positive at baseline and had anti-JCV antibody index >0.9 (median 3.36). There were no serious adverse events, including progressive multifocal leukoencephalopathy. All of the patients were transitioned to vedolizumab. CONCLUSIONS: In our experience, natalizumab is a safe and efficacious medication in pediatric in patients with inflammatory bowel disease. Given the favorable results with natalizumab, pediatric studies with the more gut targeted anti-integrin agent vedolizumab are warranted.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Enfermedad de Crohn/tratamiento farmacológico , Natalizumab/uso terapéutico , Adolescente , Niño , Enfermedad de Crohn/virología , Femenino , Humanos , Virus JC , Masculino , Inducción de Remisión , Estudios Retrospectivos , Centros de Atención Terciaria
18.
J Pediatr Gastroenterol Nutr ; 60(1): 27-9, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25162366

RESUMEN

BACKGROUND: Ulcerative colitis (UC), a chronic inflammatory disease of the large intestine, is characterized by a dysregulated immune reaction. UC is associated with fecal dysbiosis. Human and animal studies support the fact that the gastrointestinal microbiome may trigger the intestinal immune response, resulting in UC. Fecal microbial transplantation (FMT), by changing the gastrointestinal microbiome of patients with UC, may be a therapeutic option. METHODS: Four patients with moderate symptoms defined by the Pediatric Ulcerative Colitis Activity Index were enrolled in a prospective, open-label study of FMT via nasogastric tube in pediatric UC (US Food and Drug Administration IND 14942). After the donor and patient evaluation, patients received FMT with follow-up evaluations at 2, 6, and 12 weeks after transplantation. Study subjects were maintained on their pretransplant medications. The Pediatric Ulcerative Colitis Activity Index score, C-reactive protein, and stool calprotectin were completed during each study visit. RESULTS: Four patients with UC were enrolled (all boys). Ages ranged from 13 to 16 years. Patients tolerated FMT without adverse effects. None of the patients clinically improved with FMT, nor were there any significant changes in stool calprotectin or laboratory values, including C-reactive protein, albumin, and hematocrit. Three individuals received additional standard medical therapies before the end of the study. CONCLUSIONS: This study, although showing that single-dose FMT via nasogastric tube is well tolerated in active pediatric UC, did not show any clinical or laboratory benefit.


Asunto(s)
Colitis Ulcerosa/terapia , Microbiota , Terapias en Investigación , Adolescente , Antiinflamatorios no Esteroideos/uso terapéutico , Colitis Ulcerosa/tratamiento farmacológico , Colitis Ulcerosa/microbiología , Colitis Ulcerosa/fisiopatología , Terapia Combinada/efectos adversos , Selección de Donante , Heces/microbiología , Estudios de Seguimiento , Hospitales Pediátricos , Humanos , Inmunosupresores/uso terapéutico , Intubación Gastrointestinal , Masculino , Servicio Ambulatorio en Hospital , Probióticos/uso terapéutico , Índice de Severidad de la Enfermedad , Terapias en Investigación/efectos adversos , Washingtón
19.
J Pediatr Gastroenterol Nutr ; 60(1): 23-6, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25162365

RESUMEN

Fecal microbiota transplantation (FMT) is a safe and effective therapy for adults with recurrent Clostridium difficile colitis, but data regarding FMT in children are limited and focus on colonoscopic administration of FMT. We present 10 consecutive children who received FMT via nasogastric tube for treatment of recurrent C difficile infection. Median age was 5.4 years, and 30% were receiving simultaneous immunosuppression. Median follow-up was 44 days, and 90% of patients resolved their C difficile infection; one patient relapsed 2 months later after receiving antibiotics. FMT via nasogastric tube appears safe, well tolerated, and effective in treating pediatric recurrent C difficile colitis.


Asunto(s)
Clostridioides difficile/aislamiento & purificación , Enterocolitis Seudomembranosa/terapia , Microbiota , Terapias en Investigación , Niño , Preescolar , Clostridioides difficile/crecimiento & desarrollo , Clostridioides difficile/inmunología , Comorbilidad , Selección de Donante , Enterocolitis Seudomembranosa/epidemiología , Enterocolitis Seudomembranosa/inmunología , Enterocolitis Seudomembranosa/microbiología , Heces/microbiología , Femenino , Estudios de Seguimiento , Hospitales Pediátricos , Humanos , Huésped Inmunocomprometido , Intubación Gastrointestinal , Masculino , Recurrencia , Estudios Retrospectivos , Terapias en Investigación/efectos adversos , Washingtón/epidemiología
20.
J Environ Biol ; 36(4): 903-8, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26364468

RESUMEN

Lignocellulosic biomass can be used as a low cost substrate for cellulase production. In the present study an attempt was made to optimize physicochemical condition standardization for simultaneous cellulase production by NSF-2 fungal isolate, using wheat straw as a substrate and enzymatic hydrolysis of wheat straw by cellulase produced in-vitro by NSF-2 fungal isolate. Experiments showed maximum saccharification after 5th day of incubation. Optimum pH and temperature for saccharification were 5 and 30 degrees C respectively. Further optimization was carried out by response surface methodology using Box-Behnken design (BBD). BBD was designed with different combinations of three variables (peptone as nitrogen source, lignocellulosic biomass as substrate and Tween--80 as surfactant, each at three levels 1 g l(-1), 2 g l(-1), 3 g l(-1), 0.5 g l(-1), 2.5 g l(-1), 5 g l(-1) and (0.05%, 0.10%, 0.15%) respectively. The model computed for R2 value (99.55%) indicated that this was appropriate and could be useful in predicting the effect of the studied variables. Experimental results showed maximum saccharification at the middle concentration of peptone and substrate, i.e., 2 g l(-1) and 2.5 g l(-1) respectively. Surfactant did not show much significant result.


Asunto(s)
Celulasa/biosíntesis , Proteínas Fúngicas/metabolismo , Lignina/metabolismo , Estadística como Asunto , Biomasa
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA